Galunisertib

CAT: 0421-82601Size: 25 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0421-82601Size:25 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Background

Galunisertib, or LY2157299 monohydrate) is a highly potent and selective inhibitor of TGF-β (transforming growth factor β) receptor I kinase that binds to the ATP-binding site of the protein. The TGF-β superfamily is critical for the development of cells and tissues, and their continued homeostasis. In the context of cancer, TGF-β signaling plays a protective role in the early stages of the disease, but as promoter at later stages, which abnormal signaling being implicated in glioblastoma, breast cancer and others. Targeting this pathway has thus gained interest in oncology. Galunisertib was shown to inhibit tumor growth in animal models of cancer, but exposure in the long term resulted in cardiac toxicity. It is currently being studied in a phase Ib/II clinical trial for the treatment of solid tumors and NSCLC (non-small cell lung cancer) in combination with nivolumab, a monoclonal antibody that blocks PD-1 (programmed cell death 1) .

Description

Galunisertib is a TGF-β kinase (ALK5) antagonist.

CAS Number

700874-72-2

Purity

≥ 98% by NMR

Solubility

Soluble in DMSO (up to 25 mg/mL)

Molecular Formula

C22H19N5O

Shipping Conditions

-20°C

Storage Conditions

Upon receipt, store at -20°C. Stable for 1 year from date of receipt, when stored as directed. Solutions are stable for up to 1 month at -20°C.

Calculated Molecular Weight

369.43 Da

Alternative Products

Catalog	Name
HY-13226-01	Galunisertib
C08376-10mM/1mL	Galunisertib (LY2157299)
HY-13226R-01	Galunisertib (Standard)
GTR19212490-01	Galunisertib Monohydrate
HY-13226A	Galunisertib (monohydrate)

Galunisertib

Alternative Products

Popular Products